MEDICINOVA INC
MNOVNasdaq
$1.35
↓ -4.9%Jul 17 close · end-of-day
Price
1Y↑ +10.7%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$66.4M
Enterprise Value
$39.1M
P/E
—
P/S
—
P/B
1.7
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
$12.3M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
31.1%
ROIC
-84.5%
Debt / Equity
—
Net Cash
$27.3M
Return 1Y
+9.8%
Company profile
MediciNova, Inc. focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders. MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist for the. treatment of acute exacerbations of asthma, MN-001 (tipelukast) is an orally bioavailable small molecule compound to treat fibrotic diseases.
- CEO
- Yuichi Iwaki
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 10
- Headquarters
- California
- Website
- medicinova.com
Earnings
MNOV Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$186,984.00—
Diluted EPS-$0.05↓ -16.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | — | $4.0M | — | $1.0M | — | $409,657.00 |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$14.2M | -$10.2M | -$14.6M | -$9.9M | -$12.7M | -$13.3M |
| Net income | -$13.9M | -$10.1M | -$14.1M | $8.6M | $11.1M | $12.0M |
| Diluted EPS | — | -$0.21 | -$0.29 | -$0.17 | -$0.23 | -$0.24 |
| Operating cash flow | -$10.8M | -$9.4M | -$12.9M | -$7.4M | -$10.6M | -$9.8M |
| Free cash flow | -$10.9M | -$9.4M | -$12.9M | -$7.5M | -$10.6M | -$9.8M |
| Gross margin | — | — | — | — | — | — |
| Operating margin | — | -253.0% | — | -990.0% | — | -3242.5% |
| Net margin | — | -251.0% | — | 857.2% | — | 2928.8% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $134,599.00 | $123,319.00 | — | $186,984.00 |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$3.0M | -$3.3M | -$3.2M | -$3.2M | -$3.6M | -$3.4M | -$3.1M | -$2.8M |
| Net income | -$2.6M | -$2.9M | $19.3M | -$2.9M | -$3.3M | -$3.1M | $21.2M | -$2.6M |
| Diluted EPS | -$0.05 | -$0.06 | -$0.06 | -$0.06 | -$0.07 | -$0.06 | -$0.05 | -$0.05 |
| Operating cash flow | -$2.8M | -$2.0M | -$1.9M | -$3.8M | -$2.3M | -$1.7M | -$2.0M | -$3.5M |
| Free cash flow | — | -$2.0M | — | -$3.8M | — | — | — | -$3.5M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | -2679.9% | -2741.7% | — | -1516.6% |
| Net margin | — | — | — | — | -2437.7% | -2473.6% | — | -1383.1% |
Company news
Jun 8, 2026
- 42d agoAlcohol Use Disorder Market Set to Expand at a 12.1% CAGR During the Forecast Period (2026–2036), Owing to the Emergence of Novel Mechanisms Such as 5-HT3 Pathway, NOP Receptor, mGluR5 NAM, and Other | DelveInsightfinance.yahoo.com
- 42d agoMediciNova Receives Notice of Allowance for New Patent Covering Use of MN-166 in Combination with Anti-PD-1 Immune Checkpoint Inhibitor for Glioblastoma Treatmentfinance.yahoo.com
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.